Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07209462 · ClinicalTrials.gov registry record · Phase 2

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

A Phase 2 study of Fragile X Syndrome, sponsored by Mirum Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
15
Study locations

NCT07209462: Recruiting Phase 2 study of Fragile X Syndrome, sponsored by Mirum Pharmaceuticals.

NCT07209462 is a Phase 2 study of Fragile X Syndrome that is actively recruiting participants, run by Mirum Pharmaceuticals. The registered enrollment target is 60 participants, below the 98-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (39% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07209462, a Phase 2 study of Fragile X Syndrome, is actively recruiting participants, sponsored by Mirum Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
15
Study locations

Study Summary

This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of MRM-3379 in male participants with Fragile X Syndrome ages 16 to 45 (inclusive). In addition, a parallel cohort of participants ages 13 to \<16 will receive open-label MRM-3379. All participants will participate for 12 weeks of treatment. The study is also intended as a proof-of-concept investigation to evaluate whether MRM-3379 can improve FXS symptoms

Conditions Studied

Fragile X Syndrome

Interventions

  • DRUG Placebo
  • DRUG Low dose of MRM-3379
  • DRUG Middle Dose of MRM-3379
  • DRUG High dose of MRM-3379
  • DRUG Low dose of MRM-3379 Open-Label

Study Locations (15)

California

  • Amnova Clinical Research, LLC - Irvine
  • Children's Hospital of Orange County - Pediatric Subspecialty - Orange
  • Uc Davis Mind Institute - Sacramento

Massachusetts

  • Boston Children's Hospital - Boston
  • UMass Memorial Health - Worcester

Arizona

  • Southwest Autism Research & Resource Center - Phoenix

Colorado

  • Children's Hospital Colorado - Aurora

Florida

  • Neurology - Miami

Georgia

  • Emory University - The Emory Clinic - Clifton Road - Atlanta

Illinois

  • Rush University Medical Center-Clinical Operation - Chicago

Maryland

  • Kennedy Krieger Institute, John Hopkins School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-11-22
Est. Completion 2027-10
Phase Phase 2
Mirum Pharmaceuticals

28 total trials

What NCT07209462 shows while recruiting

NCT07209462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 98-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (39% lower).

The record links to 1 condition, with Fragile X Syndrome appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT07209462 lists 15 locations in 12 states (California, Massachusetts, Arizona).

Frequently Asked Questions

What is clinical trial NCT07209462 about?

NCT07209462 is a clinical study titled "Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)". This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of MRM-3379 in male participants with Fragile X Syndrome ages 16 to 45 (inclusive). In addition, a parallel cohort of participants ages 13 to \<16 will receive open-label ...

What is the current status of trial NCT07209462?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-11-22. Estimated completion is 2027-10.

What conditions does trial NCT07209462 study?

This clinical trial studies the following conditions: Fragile X Syndrome.

What interventions are being tested in trial NCT07209462?

The interventions under investigation include: Placebo (DRUG), Low dose of MRM-3379 (DRUG), Middle Dose of MRM-3379 (DRUG), High dose of MRM-3379 (DRUG), Low dose of MRM-3379 Open-Label (DRUG).

Who is sponsoring clinical trial NCT07209462?

This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07209462 being conducted?

This trial has 15 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fragile X Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07209462's enrollment target sits among peer trials

60 9th of 16 higher than 7 of 16 other Fragile X Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fragile X Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07209462

Source: ClinicalTrials.gov NCT07209462, the US trial registry maintained by the National Library of Medicine. NCT07209462 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.